06/02/2026
We were trying to buy time for exactly this kind of medicine. Instead, we squandered the one thing she couldn’t afford to lose. Time.
This article screamed "FAILURE" in my face last night. I had to read it in bite sized chunks because it was like being repeatedly hit in the face with a baseball bat. It validated the strategic direction I believed oncology needed to move toward while Emily was still alive - except I ignored my gut.
This paper, as far as I'm concerned, is not fundamentally about “a melanoma drug.”
It is about:
• individualized neoantigen targeting
• adaptive immune activation
• durable T cell memory
• multi-modal biological suppression
• genomic, individualized, all-out tumor warfare
First: This maps directly onto the framework I was already gravitating toward: Hold the tumor in check long enough for adaptive precision therapies to mature.
Second: Neoantigen therapies depend on the immune system recognizing tumor specific abnormal proteins created by mutations. If the tumor remained biologically contained long enough, emerging individualized immunologic approaches might have become viable.
And of course, third: If you engage individualized immune surveillance early enough in high risk disease, you can materially alter long term recurrence trajectories, thus making my theory NOT theoretical anymore. Actual durable separation in recurrence free survival and distant metastasis free survival.
This article is incredibly thorough and outlines how what I wrote in the white papers becomes reality: create tumor stalemate, recognize that HGG equals multimodal treatment, engage the body’s immune system by preventing the tumor from hiding, and most critically, treat the individual, not the condition.
The damned bridge collapsed before we could cross it. This should be validation but it feels more like the anatomy of a preventable collapse.
Our clinical approach to serious, complex disease has to change. It has to start with the human blueprint, not the billing pathway, the protocol shortcut, or the administrative maze. Strip away the waste. Give clinicians room to think, adapt, and fight for the individual patient in front of them. That’s where the next bridge gets built. Otherwise, we stay on the same slow, methodical path that keeps widening the patient care gap instead of closing it.
For Emily...Dad is still fighting. Forever loved. Forever 24. 🩶
Intismeran autogene (intismeran; formerly V940 or mRNA-4157) is an mRNA-based individualized neoantigen therapy. We report 5-year outcomes of intismeran plus pembrolizumab from the phase 2b KEYNOTE-942 study (NCT03897881). Eligible patients with resected ...
